Observational Study
Copyright ©The Author(s) 2023.
World J Gastroenterol. Oct 21, 2023; 29(39): 5494-5502
Published online Oct 21, 2023. doi: 10.3748/wjg.v29.i39.5494
Figure 1
Figure 1 Kaplan-Meier analysis. A and B: Kaplan-Meier analysis for time to incident venous thromboembolism in the UK Biobank during the entire follow-up period for inflammatory bowel disease (IBD) patients (A) and cancer patients (B); C and D: Within the 3 years after IBD diagnosis for IBD patients (C) and cancer patients (D). IBD: Inflammatory bowel disease.
Figure 2
Figure 2 Proportion of incident venous thromboembolism in the UK Biobank by carrier status of F5 factor V leiden and/or F2 prothrombin gene mutation, decile of polygenic scorenonF5/F2, and decile of original polygenic score. Dot and vertical line indicate mean and 95% confidence interval, respectively. A: Carrier status of F5 factor V leiden and/or F2 prothrombin gene mutation; B: Decile of polygenic score (PGS)nonF5/F2; C: Decile of original PGS. Dot and vertical line indicate mean and 95% confidence interval, respectively. VTE: Venous thromboembolism.